Episode 69:DUPLEX Sparsentan, it’s no Acthar Gel

The Filtrate:

Joel Topf

Swapnil Hiremath

Priya Yenebere

Nayan Arora

With Special Guest:

Brendon Neuen Super smart guy and clinical trialist

Michelle Rheault Lead author of DUPLEX and friend of the pod

Show Notes

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

NephJC Summary | PubMed | NEJM

KDIGO FSGS Guidelines 2021 (PDF)

Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications, A Scoping Review (JAMA Internal Medicine)

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)

Vlado Perkovic, mentor and sponsor extradenoire (UNSW Sydney)

Shimer Its a floor wax and a desert topping (TikTok)

SONAR: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease: a double-blind, randomised, placebo-controlled trial. (NephJC)

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Travere press release)

GFR Slope: Chronic vs Total slope: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure (Nature Medicine)

There are dozens of us! Dozens! (Know your Meme)

Brendon’s Neuen’s tweet about total versus chronic slope (X | Twitter)

Julie R. Ingelfinger, deputy editor for the New England Journal of Medicine (Wikipedia)

You know nothing, John Snow (YouTube shorts)

Tubular Secretions

Swapn